Skip to main content
Caplight Logo









AlphaMol Science

AlphaMol Science

Private
AllschwilHealthcare & Life Scienceshttps://alphamol.com/

Last Round

Series B

Nov 1, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AlphaMol Science is a biotechnology company that leverages computational biology, artificial intelligence, and medicinal chemistry to accelerate G protein-coupled receptor (GPCR) drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

GPCR drug discoveryAI drug discoverycomputational biologyin silico drug discoveryGPCRdrug discovery platformbiotech AIlead optimizationbiochipcellular electrophysiologyvirtual screeningmolecular generationdrug pipelinebiopharma partnershippharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AlphaMol Science Comparables

Compare AlphaMol Science with similar companies based on industry and business-model similarity.

AlphaMol Science comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
InterAx Biotech
83%
In Virtuo Laboratories SA
80%
Genesis Therapeutics
80%

AlphaMol Science Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 1, 2025
Series AAug 24, 2023
AngelMay 7, 2021

AlphaMol Science Investors

Notable investors and investment history

AlphaMol Science investors
InvestorRounds
Shanghai Healthcare CapitalSeries A
Huaqian CapitalSeries A
CICC CapitalSeries B
Shenzhen New Henglida Capital ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2025

    Raised Series B round with CICC Capital as an investor.

  • Jun 1, 2025

    Monthly visitors grew 56% MoM.

AlphaMol Science Filings

Explore SEC and related filing metadata, where available.

AlphaMol Science filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AlphaMol Science's valuation, stock price, and market status.

Is AlphaMol Science a public or private company?

AlphaMol Science is a private company.

What is the current stock price of AlphaMol Science?

AlphaMol Science is a private company with no public stock price. Caplight tracks AlphaMol Science's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is AlphaMol Science worth (valuation)?

Valuation information for AlphaMol Science is not publicly available.

Can I buy AlphaMol Science stock?

AlphaMol Science shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AlphaMol Science's last funding round?

AlphaMol Science's most recent funding round was Series B on November 1, 2025.

Who are the main investors in AlphaMol Science?

Key investors in AlphaMol Science include Shanghai Healthcare Capital.

Will AlphaMol Science IPO soon?

No public IPO plans have been announced for AlphaMol Science.

How can I track AlphaMol Science secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AlphaMol Science's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAllschwil
Employee Range3
Year Founded2020
Last FundingNov 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?